Monsanto Company and Complix NV Sign Collaboration to Bring New Technologies to Agriculture

ST. LOUIS and HASSELT, Belgium, September 20, 2012 /PRNewswire/ –

Monsanto Company and Complix NV today announced they have entered into a collaboration
agreement to evaluate and develop Complix’s proprietary Alphabody(R) protein technology in
the field of agriculture.

Complix is a biopharmaceutical company focused on the discovery and development of its
Alphabody(R) technology platform. Alphabodies are a unique class of protein therapeutics
that are potentially active against a broad range of disease targets, including
intracellular targets. Alphabodies are small single chain alpha-helical proteins that are
designed by computer modelling, but are inspired by naturally existing protein structures.
This collaboration represents the first application of Complix’s Alphabody(R) technology
in agriculture.

“Complix’s expertise in protein targeting technology offers a novel platform to
further enhance our trait development capabilities,” said Bob Reiter, Monsanto’s Vice
President of Biotechnology. “We believe this technology offers great promise and could
contribute to development of new traits to protect plants from pests and diseases. We are
pleased to work with Complix to develop this promising technology in a way that might
deliver on-farm benefits to our grower customers.”

Under the terms of the agreement, Complix will grant Monsanto worldwide exclusive
rights to access Complix’s Alphabody(R) platform technology for use in plant agriculture.
Complix retains the exclusive rights on any discoveries made under this collaboration for
use outside the field of plant agriculture. The agreement also includes options to expand
the collaboration across multiple applications within plant agriculture. Further terms
were not disclosed.

“We are delighted to have concluded this agreement with Monsanto, a leading
agricultural company with a strong track record of delivering innovations to the
marketplace,” said Mark Vaeck, Chief Executive Officer of Complix NV. “By working with
Monsanto, our partner of choice for this space, I am confident that we will be able to
apply our Alphabody platform to address some of the most important challenges facing
agriculture today and tomorrow. This strategic alliance, will also enable us to create
significant value for our shareholders as it will contribute to further strengthening and
expanding our Alphabody platform and help Complix to establish its leadership position in
the field of cross-over therapeutics.”

About Monsanto Company

Monsanto Company is a leading global provider of technology-based solutions and
agricultural products that improve farm productivity and food quality. Monsanto remains
focused on enabling both small-holder and large-scale farmers to produce more from their
land while conserving more of our world’s natural resources such as water and energy. To
learn more about our business and our commitments, please visit: http://www.monsanto.com.
Follow our business on Twitter(R) at http://www.twitter.com/MonsantoCo, on the company
blog, Beyond the Rows at http://www.monsantoblog.com, or subscribe to our News Release RSS
Feed.

About Complix NV

Complix discovers and develops Alphabodies, a novel and proprietary class of
biopharmaceuticals that delivers significant advantages over current protein therapeutic
approaches. Alphabodies comprise an alpha-helical coiled coil structure, which makes them
ideal protein scaffolds for therapeutic applications as they combine the specificity of
antibodies with small molecule-like properties. Alphabodies’ most important advantage is
their ability to address currently undruggable extracellular and, in particular,
intracellular targets.

Complix is developing cell penetrating Alphabodies (CPABs) that have the potential to
modulate intracellular PPIs, and has generated data demonstrating that CPABs are able to
enter cells, bind to disease targets and can generate biological effects at low
concentrations. CPABs have been designed to tackle the significant proportion of all known
human disease targets that are located inside cells and cannot be addressed by either
small chemical drugs or biologics. These targets belong to the most interesting class of
potential drug targets, namely intracellular protein-protein interactions (PPIs), which
are involved in important disease processes, such as those causing cancer, CNS,
inflammation or metabolic diseases.

Alphabodies’ unique design, which has been invented by the Complix founders, means
that the Company has a unique freedom-to-operate position. Complix has already established
a strong intellectual property position for its Alphabody platform through the filing of
several broad patent applications.

Complix’s current R&D focus is on the development of novel Alphabody-based therapies
for inflammation/autoimmunity and cancer.

Complix is headquartered in Hasselt (Belgium) in the Life Sciences incubator BioVille,
and has research facilities in Ghent (Belgium) and in Luxembourg. The Company has a fully
owned subsidiary in Luxembourg and a strategic alliance with the public research institute
CRP-Sante. For further information, please visit http://www.complix.com.

        Contacts
        Complix NV
        Dr. Mark Vaeck, CEO
        +32-9-261-69-40
        mark.vaeck@complix.com

SOURCE Complix